CtDNA Based MRD Testing for NAC Monitoring in TNBC
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- Personalis Inc.
- Study ID
- NCT06230185
- Status
- Recruiting
Conditions
- Minimal Residual Disease
- TNBC - Triple-Negative Breast Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Key Dates
- Start date
- Nov 9, 2023
- Status verified
- Jan 2025
- Primary completion
- Aug 30, 2025
- Completion
- Dec 31, 2025
Study Design
- Enrollment
- 422 participants (estimated)
Primary Outcome Measure
Evaluate the correlation of MRD to pCR after NAC in TNBC [ Time Frame: through study completion, an average of 6 months ]
Central Contacts
- Soumya Chappidi484-704-2599
- Julee Hartwell607-651-6273
Locations (14)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Arizona Oncology | Tucson | Arizona | 85704 | Rachel Swart, MD |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | Peter Kabos, MD |
| George Washington University | Washington D.C. | District of Columbia | 20037 | Pavani Chalasani, MD |
| Mount Sinai Medical Center of Florida | Miami Beach | Florida | 33140 | Oleg Gligich, MD |
| Comprehensive Hematology Oncology (ONare Alliance, LLC / Exigent Research, LLC | St. Petersburg | Florida | 33709 | Neeharika Makani, MD |
| Illinois Cancer Care | Peoria | Illinois | 61615 | Nadia Rehman, MD |
| Louisiana State University | New Orleans | Louisiana | 70112 | Michelle Loch, MD |
| Trinity Health-Michigan | Ypsilanti | Michigan | 48197 | Tareq Al Baghdadi, MD |
| Nebraska Methodist | Omaha | Nebraska | 68114 | Kristen Leu, MD |
| Stony Brook University Cancer Center | Stony Brook | New York | 11794 | Alison Stopeck, MD |
| Oregon Oncology Specialists | Salem | Oregon | 97301 | Janelle Meyer, MD |
| Cancer Care Associates of York | York | Pennsylvania | 17403 | Joyce Huang, MD |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Carlos Hernando Barcenas, MD |
| Cancer Care Northwest | Spokane | Washington | 99202 | Kristen Rinn, MD |
Find similar trials in Tucson, AZ
By research site
Arizona Oncology· Tucson, AZUniversity of Colorado Cancer Center· Aurora, COGeorge Washington University· Washington D.C., DCMount Sinai Medical Center of Florida· Miami Beach, FLComprehensive Hematology Oncology (ONare Alliance, LLC / Exigent Research, LLC· St. Petersburg, FLIllinois Cancer Care· Peoria, IL
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- Caris Biorepository Research ProtocolRecruiting · Caris Science, Inc. · Mobile, Alabama
- HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell TransplantPHASE1 · Recruiting · Fred Hutchinson Cancer Center · Seattle, Washington
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey